United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Takes $12.95 Million Position in United Therapeutics Corporation $UTHR

Key Points

• United Super Pty Ltd disclosed a new position in United Therapeutics, buying 26,583 shares worth about $12.95 million in the fourth quarter. The stake represents roughly 0.06% of the company.
• Institutional ownership remains very high, with hedge funds and other institutions holding about 94.08% of United Therapeutics’ shares. Several other funds also reported modest increases in their positions.
• The company faces mixed signals: analysts remain broadly positive with multiple buy/outperform ratings and higher price targets, but recent quarterly results missed EPS and revenue estimates, and insider selling by the CFO and CEO has pressured sentiment.

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund bought a new stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 26,583 shares of the biotechnology company's stock, valued at approximately $12,953,000. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund owned approximately 0.06% of United Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Clearstead Advisors LLC boosted its holdings in shares of United Therapeutics by 8.9% in the third quarter. Clearstead Advisors LLC now owns 280 shares of the biotechnology company's stock valued at $117,000 after acquiring an additional 23 shares in the last quarter. Independent Advisor Alliance boosted its holdings in United Therapeutics by 3.3% during the fourth quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company's stock worth $406,000 after buying an additional 27 shares in the last quarter. Bessemer Group Inc. boosted its holdings in United Therapeutics by 2.6% during the third quarter. Bessemer Group Inc. now owns 1,126 shares of the biotechnology company's stock worth $472,000 after buying an additional 28 shares in the last quarter. Archer Investment Corp boosted its holdings in United Therapeutics by 9.5% during the third quarter. Archer Investment Corp now owns 356 shares of the biotechnology company's stock worth $149,000 after buying an additional 31 shares in the last quarter. Finally, Signaturefd LLC boosted its holdings in United Therapeutics by 4.1% during the fourth quarter. Signaturefd LLC now owns 896 shares of the biotechnology company's stock worth $437,000 after buying an additional 35 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company's stock.

More United Therapeutics News

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: United Therapeutics said it will present at the Jefferies Global Healthcare Conference, keeping the company visible to investors and highlighting ongoing engagement with the healthcare investing community. Article Title
• Positive Sentiment: The company also shared updates on its PHINDER screening study and its xenokidney/EXTEND trial, which could support the long-term growth story if the clinical programs continue to progress. Article Title Article Title
• Neutral Sentiment: The stock remains supported by a generally constructive analyst backdrop, with several firms maintaining buy or outperform ratings and some raising price targets, which can help offset near-term concerns.
• Neutral Sentiment: Short-interest data showed no meaningful change in available reported shares, so this does not appear to be a major trading catalyst.
• Negative Sentiment: CEO Martine Rothblatt sold additional United Therapeutics shares, following another recent sale, and CFO James Edgemond also sold stock. Multiple insider sales can weigh on investor sentiment, especially after the company’s recent earnings miss. Article Title Article Title
• Negative Sentiment: United Therapeutics recently reported quarterly EPS and revenue below expectations, which remains an overhang on the shares despite the company’s strong profitability.

United Therapeutics Price Performance

Shares of NASDAQ UTHR opened at $562.09 on Friday. United Therapeutics Corporation has a 12-month low of $272.12 and a 12-month high of $609.35. The company has a market capitalization of $23.86 billion, a PE ratio of 20.75, a price-to-earnings-growth ratio of 1.84 and a beta of 0.60. The firm's 50-day moving average is $565.98 and its two-hundred day moving average is $515.55.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to analysts' expectations of $797.40 million. During the same period last year, the company earned $6.63 EPS. The firm's revenue for the quarter was down 1.6% on a year-over-year basis. On average, analysts forecast that United Therapeutics Corporation will post 27.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. Wells Fargo & Company raised shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their price objective for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Raymond James Financial assumed coverage on shares of United Therapeutics in a report on Friday, April 10th. They set an "outperform" rating and a $700.00 price objective on the stock. Royal Bank Of Canada decreased their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an "outperform" rating on the stock in a report on Thursday, May 7th. TD Cowen reissued a "buy" rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Oppenheimer boosted their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday, February 26th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, United Therapeutics has an average rating of "Moderate Buy" and an average target price of $619.42.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the business's stock in a transaction that occurred on Monday, March 23rd. The shares were sold at an average price of $527.48, for a total value of $5,274,800.00. Following the completion of the transaction, the chief financial officer owned 18,876 shares of the company's stock, valued at $9,956,712.48. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 591,473 shares of company stock valued at $331,434,344 over the last ninety days. Insiders own 8.60% of the company's stock.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.